Silver Sulfadiazine Burn Ointment
Although major burns create serious medical crises, most burn deaths are attributable to infections rather than the burns themselves. Dr. Charles L. Fox Jr., a bacteriologist in a surgical unit, combined two known antibacterial agents for burns, silver nitrate and sulfadiazine, to create a synergistic compound that is extremely effective against infection. Silver sulfadiazine burn ointment was licensed to Marion Laboratories in 1969 following clinical trials to prove its efficacy.
Silver sulfadiazine quickly became the drug of choice due to its effectiveness at controlling bacterial infection and pain-free application. Produced as a water-soluble ointment, silver sulfadiazine was first employed on a large scale during the Vietnam War.
The U.S. patent for silver sulfadiazine was issued in September 1973.
- bgh Polyadenylation Signal
- Blue Noise Mask
- Cisplatin and Carboplatin Anticancer Drugs
- Deimmunized Sarcin Ribotoxin
- Endotoxin-free ClearColi™ Expression System
- Fibronectin Artificial Antibody Scaffold
- Fullerenes
- Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)
- mRNA Transport Enhancer
- PEGylation: Non-Immunogenic Delivery of Protein-Based Drugs
- Pichia Classic Expression Platform
- Pichia GlycoSwitch® Protein Expression System
- Pichia Protein Expression System
- Prostate-Specific Antigen Blood Test for Prostate Cancer
- Shingles Vaccine Antigen (Shingrix®)
- Silver Sulfadiazine Burn Ointment
- Technetium-99M Complexes for Cardiac Imaging
- The CH2 Domain Scaffold – ABDURINS™
- Ultrasound Tissue Harmonic Imaging
- VIMPAT® (lacosamide) for Treatment of Epileptic Seizures
- Viral-mediated Gene Transfer System
